Vicini D, Franceschetti G P, Mirando P, Ruggieri M, Cardellini P
Divisione di Urologia, Ospedale Civile Voghera.
Arch Ital Urol Androl. 1993 Apr;65(2):181-4.
19 patients with renal adenocarcinoma and mets were treated with INF alfa 2b (10 x 10(6) U/m square s.c. three times weekly) plus VBL (0.1 mg/kg every 3 weeks). We followed up the patients for 12 weeks with monitoring of major parameters. The outcomes have been positive in 16.6% of the cases with mean survival of 20.7 months. We point out the efficacy in lung mets. The outcomes of therapy with INF alfa 2b plus VBL are unsuccessful and we state that an alternative solution could be interleukin 2.
19例肾腺癌伴转移患者接受了α-2b干扰素（10×10⁶单位/平方米皮下注射，每周3次）加长春碱（0.1毫克/千克，每3周一次）治疗。我们对患者进行了12周的随访，并监测主要参数。16.6%的病例结果呈阳性，平均生存期为20.7个月。我们指出了对肺转移的疗效。α-2b干扰素加长春碱的治疗结果不理想，我们认为替代方案可能是白细胞介素2。
